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3-5 highlights points with an 85 character limit including spaces 
 
 Pain progression is heterogeneous in people with rheumatoid arthritis  
 Persistent pain is predicted by high disability  
 Even when inflammation resolves, the commonest trajectory is 
Persistent Pain  
 Additional pain management might help people with rheumatoid arthritis 
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Abstract  
Rheumatoid arthritis (RA) is an example of human chronic inflammatory pain. Modern 
treatments suppress inflammation, yet pain remains a major problem for many people with 
RA. We hypothesised that discrete RA subgroups might display favourable or unfavourable 
pain trajectories when receiving treatment, and that baseline characteristics will predict 
trajectory allocation. 
Growth Mixture Modelling was used to identify discrete trajectories of SF36-Bodily Pain 
scores during 3 years in 3 RA cohorts (Early RA Network (ERAN); n=683, British Society for 
Rheumatology Biologics Register Biologics (n=7090) and Non-Biologics (n=1720) cohorts. 
Logistic regression compared baseline predictor variables between trajectories. The role of 
inflammation was examined in a subgroup analysis of people with normal levels of 
inflammatory markers after 3 years. 
Mean SF36-Bodily Pain scores in each cohort improved but remained throughout 3y follow 
up >1 SD worse than the UK general population average. Discrete Persistent Pain (59% to 
79% of cohort participants) and Resolving Pain (19% to 27%) trajectories were identified in 
each cohort. In ERAN, a third trajectory displaying persistently Low Pain (23%) was also 
identified. In people with normal levels of inflammatory markers after 3 years, 65% of them 
were found to follow a Persistent Pain trajectory. When trajectories were compared, greater 
disability (aORs 2.3-2.5 per unit baseline Health Assessment Questionnaire score) and 
smoking history (aORs 1.6-1.8) were risk factors for Persistent Pain trajectories in each 
cohort. 
In conclusion, distinct trajectories indicate patient subgroups with very different pain 
prognosis during RA treatment. Inflammation does not fully explain the pain trajectories, 
and non-inflammatory factors as well as acute phase response predict which trajectory an 
individual will follow. Targeted treatments additional to those which suppress inflammation 
might reduce the long term burden of arthritis pain. 
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Perspective 
Immunosuppression reduces inflammation in RA, but pain outcomes are less favourable. 
Discrete Persistent and Resolving Pain trajectories were identified following treatment, both 
in early and established RA. Smoking and higher disability at baseline predicted persistent 
pain. Identifying patient subgroups with poor pain prognosis could enable adjunctive 
treatment to improve outcome.   
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
6 
 
Introduction 
Arthritis is a common cause of chronic musculoskeletal pain and disability; especially across 
ageing populations. Arthritis has traditionally been classified as either inflammatory (e.g. 
rheumatoid arthritis; RA) or non-inflammatory (e.g. osteoarthritis; OA, the commonest 
reason for joint replacement surgery). RA is a systemic, autoimmune condition with a 
predilection for synovial joints of the hands and feet. Synovitis (inflammation of the joint 
lining) contributes to pain, and also leads to joint damage. Important contributions of 
inflammation to OA pain are now well recognised 33, although RA remains the prototypical 
form of inflammatory arthritis. Pain is cited by patients as the most important symptom of 
RA. Early intensive immunosuppressive treatment in people with RA aims to prevent long 
term pain and disability 34. Disease modifying anti-rheumatic drugs (DMARDs) and 
glucocorticoids can reduce inflammation for many people with RA, and can also reduce pain. 
Those who do not respond adequately to conventional synthetic (cs)DMARDs might yet 
benefit from biologic (b)DMARDs such as tumour necrosis factor (TNF)α inhibitors.  
 
While clinical experience confirms that many people benefit greatly from current treatments 
34, chronic pain remains the most difficult problem for many people with RA 30. At a 
population level, average pain incompletely improves after DMARDs are commenced or 
changed 1, 30, and mean pain scores for RA populations remain worse than UK population 
mean values even 12 months after baseline 30, 31. Pain can remain problematic even when 
inflammatory disease is in remission 26, suggesting important pain mechanisms additional to 
ongoing inflammation. Central sensitisation might contribute to RA pain 22, 51, whereas joint 
damage might now be less important following introduction of effective DMARDs 7. 
Subgroups of people with RA have been identified for whom non-inflammatory mechanisms 
might contribute to ongoing pain and high clinical scores for disease activity 28, 51, and 
interest exists about whether they represent distinct phenotypes of RA. 
 
Reporting of mean effects might conceal subgroups of people with quite different outcomes, 
as people with RA display heterogeneous prognosis and response to treatment. One year 
after commencing bDMARDs, more than 50% of people with RA reported pain at 
problematic levels 30. Other studies have reported heterogeneity between individuals in the 
progression of other aspects of RA, such as trajectories of disease activity, functional 
limitations, fatigue and mental distress 11, 12, 36, 37, 45. Previous study of disease trajectories has 
focused on single study groups. However, pain trajectories might either be generic or 
specific to particular patient or treatment groups 20. Comparing different patient groups 
allows us to identify generic factors that might be amenable to interventions aiming to 
improve patient outcomes. 
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We hypothesised that patient subgroups exist that display different pain trajectories, and 
that these trajectories are shared across people with early or established RA receiving 
csDMARDs or bDMARDs. The aim of this study was to identify discrete pain trajectories in 
people with RA and then to examine factors that might explain which trajectory individuals 
will follow. We analysed data from 3 well-described hospital-based cohorts, which varied in 
disease duration and treatment regimens. The Early RA Network (ERAN) is an inception 
cohort which recruited people at physician diagnosis of RA. The 2 British Society for 
Rheumatology Biologics Registry (BSRBR) cohorts studied here recruited participants with 
established and active RA either on commencing TNFα inhibitors (BSRBR Biologics cohort) or 
not initiating bDMARD treatment (BSRBR Non-Biologics cohort). We explore whether sub-
groups with different disease progression vary as a function of treatment (BSRBR Biologics 
cohort vs BSRBR Non-Biologics cohort) or disease stage (BSRBR cohorts vs ERAN). In order to 
explore whether factors other than inflammation might determine pain progression we also 
examined pain trajectories in the sub-group of participants with normalisation of acute 
phase response and swollen joint count. 
Methods 
 
Patients and Recruitment 
 
The Early Rheumatoid Arthritis Network (ERAN) inception cohort collected data from 
outpatient clinics in the UK and Eire 16, 24. Patients were recruited when they were diagnosed 
with RA by a consultant rheumatologist. The British Society for Rheumatology Biologic 
Register (BSRBR) cohorts collected data from outpatient clinics in the UK 46. The BSRBR-
Biologics cohort recruited people who were starting biologics as part of their routine care, 
having failed to respond adequately to other DMARDs. The BSRBR-Non-Biologics cohort 
recruited people with RA who were using non-biologic DMARDs. Both BSRBR cohorts were 
observational studies of people predominantly with active RA 18. Data used for this study 
were provided for baseline, and up to 3 years follow up, between 2002 and 2013. The data 
from BSRBR were collected, stored and managed at the University of Manchester, UK. 
 
UK National Health Service ethical approvals were in place for ERAN (Trent Research Ethics 
Committee reference 01/4/047) and the 2 BSRBR cohorts (North West Multicentre Research 
Ethics Committee reference 00/8/53). All participants gave signed informed consent in line 
with the Declaration of Helsinki. 
 
Patients and Data 
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Data collection for all cohorts was from multiple centres and included physical examinations, 
interviews and reference to medical notes. Data collected that were common to all 3 
cohorts included age, sex, smoking, 28-joint disease activity score (DAS28 48, which is a 
composite score derived from erythrocyte sedimentation rate (ESR) in mm per hour, 100mm 
visual analogue scale-general health (VAS-GH), tender joint count for 28 joints (TJC) and 
swollen joint count for the same 28 joints (SJC)), body mass index (BMI), serology 
(seropositive 25 was defined as testing positive for either Rheumatoid Factor (RF) or 
citrullinated proteins according to each study centre’s normal ranges), 1987 American 
College of Rheumatology (ACR) diagnostic criteria (5/7 clinical features) 3, health assessment 
questionnaire (HAQ) for disability 6, and Short Form-36 (SF36) 50. SF-36 subscale data were 
used to estimate pain (Bodily Pain), disability (Physical Function), fatigue (Vitality) and 
psychological health (Mental Health). SF-36-Bodily Pain assesses the severity of pain and its 
impact upon daily activities 50. Pain data from people providing baseline and at least 50% of 
follow up data points were included in analyses. SF-36 data were norm transformed to the 
expected UK population estimates following standard methodology 21, 50. Briefly, this z-
transformation normalises the SF36 data from this study to the measured mean of 50 and 
standard deviation (sd) of 10 from the UK population, taking age and gender structure into 
account. Therefore a normed SF36 score of 50 is the expected average for the UK general 
population. In the BSRBR-Non-Biologics cohort, the DAS28 components were only available 
at baseline. Co-morbidities were classified as present or absent. Further to the data 
collected, rearrangements were derived of the DAS28 formula, designed to act as surrogate 
indices of central sensitisation and/or non-inflammatory pain; DAS28-P (the proportion of 
DAS28 derived from patient-reported variables, TJC and VAS-GH)22, 31 and Tender-Swollen 
Difference (TSD; TJC minus SJC)40. 
 
Statistical Analysis  
Trajectories of pain 
The norm-transformed SF36-Bodily Pain data were examined for trajectories of progression 
from baseline to 3 years. Each cohort was examined separately using the descriptive 
technique of linear growth mixture modelling (GMM) to allow the separation of latent 
subgroups of people based upon similarities between their pain trajectories. GMM is related 
to structural equation modelling, and will statistically select groups of people with similar 
trajectories. We performed GMM to produce models with increasing numbers of 
trajectories, starting with 1 trajectory, and then examined model selection criteria to inform 
the optimal model choice and the addition of another trajectory (see below). Additional 
trajectories were selected until the criteria suggested that no more should be selected, and 
there was no predetermined numbers of trajectories for each cohort.  
 
Model selection criteria 
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The Akaike Information Criteria (AIC), Bayesian Information Criteria (BIC), sample-size 
adjusted BIC (ssBIC) were used to estimate the amount of information lost within models, 
and higher values indicated worse performance. Entropy described the overall probability of 
the cases being assigned to the correct trajectory. The Lo-Mendell-Rubin likelihood ratio test 
(LMR-LRT) and bootstrap likelihood ratio test (BLRT) were significance tests comparing the 
fit for the model with k trajectories to the model with k-1 trajectories (statistical significance 
indicated an improved fit compared to the k-1 model). Trajectory membership numbers 
consisting of <5% of the sample were automatically rejected. Trajectories were named to 
describe their pain prognosis. The findings were confirmed by repeating the analyses of 
optimal trajectories while accounting for the distribution and frequency of missing data by 
using pattern mixture analysis 27, 32. This adjusted for missing data by examining pain at 
timepoint t and its association with missing pain data at timepoint t+1.  
 
Analysis of inflammation and pain 
Additional analysis was performed to assess the pain trajectories in participants with very 
low inflammation at follow up. These people were selected if they had both a 0/28 swollen 
joint count and ESR reading of ≤22 (men) or ≤29 (women) at the 3 year study visit. The GMM 
and pattern mixture models for pain trajectories were also performed in this subgroup of 
the BSRBR-Biologics cohort. 
 
Comparisons across trajectories 
Baseline differences between people allocated to each trajectory were examined using 
ANOVAs with a Bonferroni correction and Pearson Chi-square. Multinomial or binary logistic 
regression was performed to find variables that predicted membership of pain trajectories. 
The conditional probabilities of trajectory membership were used to derive probability 
weights, which were used to confirm that the logistic regression analyses were not unduly 
influenced by cases where trajectory was less certain. 
 
Progression of important clinical measures 
The mean longitudinal progression of DAS28 (the disease activity index and its composite 
variables) and HAQ-disability were plotted for the membership of each pain trajectory.  
 
Software 
GMM, pattern mixture models were performed using Mplus (Muthen and Muthen, Los 
Angeles, USA) and all other statistics and data management was performed using SPSS v22 
(IBM, Chicago, USA). 
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Results  
 
Study demographics 
Baseline demographics were similar between the 3 cohorts, except that ERAN participants 
had shorter symptom duration and were more likely to smoke, and the BSRBR-Biologics 
participants had overall more severe disease activity and disability (Table 1). Mean SF36-
Bodily Pain scores improved between baseline and first follow up (p<0.001 for each cohort), 
but remained throughout the 3 year follow up >1 SD (10 points) worse than values 
normalised to the expected UK population average (Figure 1a). 
 
Description of trajectories 
The trajectory modelling process is summarised in Table 2. For ERAN, a 3 trajectory model 
was optimal, by reference to the AIC, BIC, ssBIC, LMR-LRT and BLRT. In the BSRBR-Biologics 
and Non-Biologics cohorts, 2 trajectory models were selected. Three trajectory models were 
rejected for the BSRBR cohorts due to the small membership numbers (<4% of participants) 
in one trajectory within each 3 trajectory model (Table 2). The mean SF36-Bodily Pain scores 
over time for each trajectory are shown in Figure 1b-d. The GMMs provided probabilities for 
each person of being allocated to the correct trajectory. These are the entropy scores (Table 
2).  
 
In ERAN, the most populous of the 3 trajectories (59% of participants) showed a consistently 
high mean pain level across the 3 years (Persistent Pain trajectory). A second trajectory 
(23%) showed a consistently low mean pain level across the 3 years, approximating closely 
to the expected UK population average for Bodily Pain scores of 50 (Low Pain trajectory). 
The third trajectory (19%) showed an initially high mean pain level at baseline that improved 
approaching the expected UK population average across the three years (Resolving Pain 
trajectory; Figure 1b).  
 
In the BSRBR-Biologics cohort, each of the 2 trajectories showed improvement from baseline 
to 6 months (Figure 1c). In the most populous trajectory (79% of participants), mean Bodily 
Pain scores remained worse, by a clinically important extent, than expected UK population 
means during the 3 year follow up (Persistent Pain trajectory). In the second trajectory 
(21%), Bodily Pain scores improved to approach the expected UK population mean 
(Resolving Pain trajectory).  
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In the BSRBR-Non-Biologics cohort, 2 trajectories were again identified (Figure 1d). The most 
populous trajectory (73% of participants) showed persistent high mean pain levels 
(Persistent Pain trajectory), whereas in the other trajectory (27%) Bodily Pain scores 
improved to approach the expected UK population mean (Resolving Pain trajectory).  
 
Pain trajectories in people attaining very low inflammation 
Analysis was performed in the subgroup of people from the BSRBR-Biologics cohort with 
very low inflammation at the 3 year study visit (SJC = 0/28 and ESR ≤22 in men and ≤29 in 
women; n=1199, with n=570 giving complete SF36-Bodily Pain across all time points). This 
was performed to investigate whether those people with inflammation that returned to 
normal levels formed a single (Resolving Pain) trajectory. As in the host cohorts, in this 
subgroup the 2 trajectories of Persistent Pain (n=777, 65%) and Resolving Pain (n=422, 35%) 
were also found (see Figure 2). 
 
Baseline characteristics compared between people in discrete trajectories 
Baseline demographics, clinical measures and self-reported questionnaire scores were 
compared between trajectories. In univariate analyses (Table 3), baseline variables that 
were heterogeneous between different trajectories within each of the 3 cohorts were BMI, 
DAS28, Tender Joint Count, Tender-Swollen Difference, DAS28-P, HAQ disability scores, co-
morbidities, SF36-Physical Function, -Vitality and -Mental Health scores, and smoking status. 
In ERAN, additional pairwise analyses were performed examining the differences at baseline 
between the Persistent Pain and the Resolving Pain trajectories. Mean baseline DAS28 was 
similar between these 2 trajectories, but the Persistent Pain trajectory had significantly 
higher baseline BMI (p=0.019), Tender-Swollen Difference (p<0.001), DAS28-P (p=0.001), 
HAQ disability scores (p=0.008), more comorbidities (p=0.012), less Vitality (p=0.023), and 
fewer people that had never smoked (p=0.042) (Table 3). Baseline SF36-Bodily Pain scores 
were similar between Persistent and Resolving Pain trajectories in ERAN. 
 
Variables associated with heterogeneity were examined as independent predictors of 
allocation to each trajectory, and adjusted odds ratios were generated using multinomial 
and binary logistic regression (Table 4). The baseline variables that showed significant 
independent associations with Persistent rather than Resolving Pain trajectories in all 
cohorts were higher HAQ disability score and smoking (either current or ex-smokers; Table 
4). In ERAN, baseline variables showing significant and independent associations with Low 
rather than Persistent Pain trajectory were lower Bodily Pain, lower HAQ disability and never 
smoking (Table 4). The significant findings from the logistic regression analyses in each of the 
3 cohorts were retained when probability weightings were used to adjust for the likelihood 
of trajectory membership. 
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Secondary analyses of all cohorts (and all eligible cases) replaced DAS28 with either its 4 
components or derived variables in order to explore possibly divergent associations of pain 
trajectory with baseline inflammatory or non-inflammatory factors contributing to disease 
activity scores. When all 4 DAS28 component variables were included in the model lower 
ESR was associated with the Resolving Pain trajectories in ERAN (aOR; 0.99, 95% CI 0.98 to 
1.00) and in the BSRBR-Biologics (aOR: 1.00, 95% CI 0.99 to 1.00) cohorts, but not 
significantly so in the BSRBR-Non-Biologics cohort. Associations between other baseline 
DAS28 components or derived variables and pain trajectory did not replicate between 
cohorts. 
 
Progression of other important outcomes 
The longitudinal progression of other key clinical outcomes (DAS28 and HAQ disability) 
generally followed the progression observed in Bodily Pain scores in each pain trajectory in 
each cohort (Supplement Figure 1). People allocated to Persistent Pain trajectories displayed 
persistently high or increasing HAQ disability, and mean DAS28 scores that might initially 
improve, but remained higher than other trajectories in all cohorts. HAQ disability and 
DAS28 scores in the Resolving Pain trajectories converged with the low levels of disability 
and disease activity observed in ERAN throughout the Low Pain trajectory. Longitudinal 
progression of DAS28 components also followed pain progression in BSRBR cohort Pain 
trajectories (Supplement Figure 2). However, in ERAN, although VAS and Tender Joint Count 
remained increased in the Persistent Pain group, ESR and Swollen Joint Counts decreased by 
3 years to levels that were similar in all 3 pain trajectory groups (Supplement Figure 2). 
 
Discussion 
 
RA is an example of chronic inflammatory pain. Mean Bodily Pain scores of people with RA 
improved during treatment of inflammation, but remained worse than the expected UK 
general population average throughout 3 years follow up. However, this average conceals 
discrete subgroups of patients who experience very different favourable or unfavourable 
pain progressions. Baseline inflammation predicted good poor pain trajectories, but 
suppression of inflammation did not invariably lead to a good pain prognosis. Non-
inflammatory factors such as smoking status and disability predicted allocated to the 
Persistent Pain trajectory. Targeted treatments additional to those which suppress 
inflammation might improve prognosis in those otherwise destined to suffer chronic pain. 
 
Pain prognosis in RA 
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Many people with RA do very well on modern DMARD therapies by many measures of 
success. However, we show that a substantial majority (65%) of people achieving low 
inflammatory disease suffers from persistent pain. We previously showed that people 
presenting with active RA continued to report worse pain scores than the population 
average one year later 30, 31, and now show that pain persists over a 3 year follow up. 
Improvements in mean Bodily Pain scores following the introduction of TNF-alpha blocking 
agents appear less than might be expected from improvements in inflammatory disease 
activity, as measured by DAS28. Seventeen percent of people might report DAS28 remission 
12 months after bDMARD initiation 19, but we show that improvements occur in DAS28 
during follow up even people with persistent pain. 
 
Discrete pain trajectories in RA 
 
We found that people with clinically-determined active RA can be stratified into discrete 
groups with good or poor pain prognosis. Although pain scores in one group decreased to 
the UK general population mean, a much larger group (up to 79% of cohort participants) 
continued to report persistent and substantial pain. The Persistent Pain trajectory was 
observed even in those whose inflammatory disease responded well to treatment. Thus, for 
this subgroup pain remains a consistent clinical problem despite effective treatment of 
inflammation.  
 
Persisting and Resolving Pain trajectories were replicated across different cohorts, including 
patients with differing disease duration (early or established RA) or on different treatments 
(cDMARD or bDMARD). Discrete persistent and improving pain trajectories might also be 
observed in juvenile idiopathic arthritis 43, but have not previously been elucidated in adult 
RA. Discrete persistent and improving trajectories have been found in RA for disease activity 
scores 5, 10, psychological distress 37 or disability 36. Persistently high psychological distress or 
high disability trajectories also displayed higher baseline pain scores, and less improvement 
in pain over 3 year follow up 36, 37. However, our findings on RA pain differ in some important 
ways from these other patient outcomes. The Persistent Pain trajectories in our cohorts 
were more populous (59%-79%) than unfavourable trajectories for other outcomes of 
disease activity (2.6 to 10.7%), psychological distress (12%) 37 or disability (15 to 20%) 36. We 
showed that many people with good suppression of disease activity have persistent pain, 
and these data indicate that many people with favourable trajectories of distress or 
disability also continue to experience pain.  
 
Predictors of pain trajectory allocation and therapeutic implications 
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Persistent Pain trajectory allocation was associated with lower inflammatory (ESR) and 
worse non-inflammatory (disability, smoking) characteristics at baseline. Our observations 
that seropositivity was not significantly associated with pain trajectory, and that lower ESR 
at baseline predicted Persistent Pain trajectory allocation, contrasts with predictors of poor 
inflammatory disease prognosis. This might indicate a lesser contribution of DMARD-
modifiable inflammation to persistent pain in our patient groups. Treatments that suppress 
inflammatory disease, both csDMARDs and bDMARDs as used by patients in these cohorts, 
might be most effective at reducing pain in those with objective evidence of inflammation, 
for example raised ESR. Persistent inflammation might be expected to lead to persistent 
pain, but our findings show that Persistent Pain trajectories can be identified in people with 
little evidence of persistent inflammation. 
 
We found that greater disability and smoking status at baseline indicated patients destined 
to follow a Persistent Pain trajectory across the 3 cohorts. Disability and smoking predicted 
pain trajectory allocation independent on inflammation measures 38, and baseline disability 
and smoking similarly predicted pain prognosis in conditions not usually associated with 
joint inflammation 442. 
 
Identifying people destined to have persistent pain might help target additional pain 
management strategies that might be employed in parallel to DMARD treatment. Such 
evidence-based treatments might include cognitive behavioural therapies 41, although 
integration of medical and psychological approaches can prove challenging.  
Further research might also explore whether predictive factors (disability and smoking 
status) identified in the current study indicate non-inflammatory pain mechanisms that are 
amenable to specific interventions. Increasing physical activity can reduce musculoskeletal 
pain 13, 49. Supervised exercise in RA can reduce both pain and disability 4, suggesting a direct 
link between maintaining activity and improved pain prognosis. Smoking might alter pain 
processing 42, inflammatory disease activity 8, or response to treatment. Possible effects of 
smoking cessation interventions on RA pain deserve further study.  
 
Beyond baseline variables measured in the current study, other factors might be important 
in driving persistent pain in RA, including alterations in pain processing such as central 
sensitisation. Central sensitisation can also inflate DAS28 22, 35, 39, 40, 47 and non-inflammatory 
mechanisms might explain our finding that DAS28 itself predicted pain prognosis during 
DMARD therapy less well than did the objective measure of inflammation, ESR. A high 
proportion of DAS28 derived from patient reported components (high DAS28-P) at baseline 
22, or a higher Tender-Swollen Joint Count difference 40 in those allocated to the Persistent 
Pain trajectory might suggest greater central sensitisation 29. Tender-Swollen Difference 
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predicted pain trajectory in people with early RA in the current study, but these derived 
measures did not significantly predict pain trajectory in established disease. Similarly, others 
have not found derived measures to predict other outcomes in established RA 9, 23. Further 
research would be needed to determine whether improved measures of central 
sensitisation, for example using quantitative sensory testing, might predict pain prognosis 
better than DAS28 derived measures.  
 
Study limitations 
 
Our study is subject to a number of limitations. Each cohort was analysed separately and in 
parallel, and the baseline variables were not matched between cohorts. This limits 
comparisons between cohorts, but our consistent findings between cohorts suggest 
generalisability. Scales focussing on other aspects of pain, or with different sensitivities, 
might have produced different results to the SF36-Bodily Pain subscale. Different patient 
experiences after baseline assessment might alter psychological processes that moderate 
their interpretation and experience of pain 14, 15, in addition to any effects of inflammatory 
disease. Effects of psychosocial risk factors on the different pain trajectories in people with 
RA deserve further attention in order to identify modifiable risks that might be targets for 
specific intervention. It is possible that different pain trajectories would be detected in other 
treatment contexts, such as clinical trials or in people already undergoing stable treatment. 
Furthermore we would be optimistic that different treatment regimens might increase 
patient allocation to Resolving Pain trajectories, which only accounted for approximately 
one quarter of our study populations. The Low Pain trajectory identified in ERAN, 
characterised by low pain at baseline, was not replicated in the BSRBR cohorts. This is likely 
due to eligibility criteria for inclusion in BSRBR requiring high disease activity and 
recruitment taking place at a time when new medications were being prescribed. People 
commencing biologics in the UK usually have DAS28 > 5.134) and are highly symptomatic. 
Conversely, ERAN participants were not recruited based upon any thresholds of disease 
activity measurements (beyond those required to achieve diagnosis). Another reason for this 
different trajectory in ERAN might be that pain in early RA might be more amenable to 
successful DMARD treatment. Current practice is guided by evidence that intensive early 
treatment of RA improves long term outcomes 17, 34.  
 
Conclusions 
 
Persistent pain remains a major clinical challenge in RA, despite modern treatment of 
inflammation. Our data indicate that discrete groups of people with RA are destined to 
experience persistent or resolving pain. Persistent Pain trajectories cannot be adequately 
explained by persistent inflammatory disease activity, and this might reflect life style factors 
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or central sensitization, both of which might be amenable to intervention. Inflammation 
might also contribute to pain in other forms of arthritis, including OA 33. However, if 
suppressing inflammation alone does not prevent persistent pain in RA, then anti-
inflammatory approaches are unlikely to provide a complete solution for chronic pain in 
these other conditions. Further work might investigate the aetiology of pain in joints with no 
evidence of inflammation. RA provides an important human model of pain in which 
inflammation and non-inflammatory factors interact. Identifying subgroups destined to 
display different pain trajectories should help improve clinical trial design, treatment 
allocation and, ultimately, pain outcomes for people with RA. 
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Table 1: Baseline demographics and clinical data of participants 
 
Table 1: Sample sizes, means (standard deviations) and percentages are shown for baseline demographics. Complete 
cases; the subgroup of Data Set for whom SF36-Bodily Pain data are available for all time points. BMI= body mass 
index; DAS28= Disease Activity Score in 28 joints; HAQ=health assessment questionnaire for disability; CRP= C-
reactive protein.  
 
Table 2: Summary of the model selection process  
 
Table 2: Indices and statistics for GMMs using complete cases are shown for models with different numbers of 
trajectories.  ERAN=Early RA Network; BSRBR=British Society for Rheumatology Biologics Register; AIC= Akaike’s 
information criterion; BIC= Bayesian information criterion; ssBIC= sample size-adjusted BIC; LRT= Lo-Mendell-Rubin 
likelihood ratio test p value; BLRT= Bootstrapped likelihood ratio test P value. The selected model for each cohort 
study is shown in bold. 
 
Table 3: Comparison of baseline variables between trajectories 
 
Table 3: Mean (standard deviation) or percentages are shown for each latent trajectory at baseline. P values for 
heterogeneity between trajectories are shown. In the ERAN data set, significance in pairwise comparisons between 
Persistent Pain and Resolving Pain trajectories are indicated (* p<0.05 with Bonferonni correction). Higher scores in 
the SF36 subscales reflect better quality of life. BMI= body mass index; DAS28= Disease Activity Score in 28 joints; 
VAS-GH=visual analogue scale; TJC= tender joint count; SJC= swollen joint count; HAQ=health assessment 
questionnaire for disability; ESR= erythrocyte sedimentation rate; CRP= C-reactive protein; Seropositive= positive for 
Rheumatoid factor or citrullinated proteins. 
 
Table 4: Multinomial logistic regression for Persistent Pain trajectory in each cohort 
 
Table 4: In ERAN the adjusted odds ratios (aOR) for Persistent Pain are displayed, compared to each of the other 
trajectories. Persistent Pain was used as the reference category, and the aOR and CI’s were then inverted. 
Multinomial logistic regression was performed; and each aOR indicates the change in risk per unit increase (per year 
of age, unit of BMI, year of duration, unit of DAS28, unit of HAQ, per point of SF36 subscale). Higher scores in the 
SF36 subscales reflect better quality of life. Categorical variables aORs showed risks for comorbidities (Yes) and 
current smoker or ex-smoker compared to never smoked. Statistically significant findings are presented in bold. 
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Figure 1: Changes over time in reported bodily pain in RA cohorts 
 
Figure 1.  
A: Mean SF36-Bodily Pain normed values at each time point are given for (A) each cohort and at each time point 
from the trajectories yielded by the GMM analysis (B, C, D). B. ERAN cohort. “Low Pain” (23%), “Persistent Pain” 
(59%) and “Resolving Pain” (19%).  C. BSRBR-Biologics cohort. “Persistent Pain” (78%) and “Resolving Pain” (22%).  D. 
BSRBR-Non-Biologics cohort. “Persistent Pain” (78%) and “Resolving Pain” (22%). A normed SF36 Bodily Pain score of 
50 represents the UK population mean. Higher scores in the SF36 subscales reflect better quality of life. 
 
Figure 2: Trajectories of bodily pain in people with RA with low inflammation measures after 3 years of follow up 
 
Figure 2 
Mean values of SF36-Bodily Pain for each trajectory in our sensitivity analysis of people in the BSRBR Biologics cohort 
who showed a 0/28 swollen joint count and ESR reading of ≤22 (men) or ≤29 (women) at the 3 year study visit 
(n=1199, with n=570 providing complete pain data). The average pain score for the UK general population is shown 
as 50. Numbers were not sufficient for analysis in the ERAN cohort (n=180, with n=64 providing complete pain data). 
Follow up data for these variables were unavailable for BSRBR-Non-Biologics cohort. A normed SF36 Bodily Pain 
score of 50 represents the UK population mean. Higher scores in the SF36 subscales reflect better quality of life. 
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Figure 1: Changes over time in reported bodily pain in RA cohorts 
 
Figure 1.  
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A: Mean SF36-Bodily Pain normed values at each time point are given for (A) each cohort and at each time point from the trajectories yielded by the GMM analysis (B, C, D). 
B. ERAN cohort. “Low Pain” (23%), “Persistent Pain” (59%) and “Resolving Pain” (19%).  C. BSRBR-Biologics cohort. “Persistent Pain” (78%) and “Resolving Pain” (22%).  D. 
BSRBR-Non-Biologics cohort. “Persistent Pain” (78%) and “Resolving Pain” (22%). A normed SF36 Bodily Pain score of 50 represents the UK population mean. Higher scores 
in the SF36 subscales reflect better quality of life. 
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Figure 2 
 
Figure 2 
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Mean values of SF36-Bodily Pain for each trajectory in our sensitivity analysis of people in the BSRBR Biologics cohort who showed a 0/28 swollen joint 
count and ESR reading of ≤22 (men) or ≤29 (women) at the 3 year study visit (n=1199, with n=570 providing complete pain data). The average pain score for 
the UK general population is shown as 50. Numbers were not sufficient for analysis in the ERAN cohort (n=180, with n=64 providing complete pain data). 
Follow up data for these variables were unavailable for BSRBR-Non-Biologics cohort. A normed SF36 Bodily Pain score of 50 represents the UK population 
mean. Higher scores in the SF36 subscales reflect better quality of life. 
 
 
Table 1: Baseline demographics and clinical data of participants 
 
  ERAN   BSRBR-Biologics   BSRBR-Non-Biologics 
  All cases 
Complete 
cases 
  All cases 
Complete 
cases 
  All cases 
Complete 
Cases 
Sample size 683 264 
 
7090 3138 
 
1720 605 
Age  57 (13) 56 (14) 
 
57 (11) 57 (11) 
 
61 (12) 62 (12) 
Female % 66% 71% 
 
77% 77% 
 
75% 75% 
BMI  28 (5) 28 (5) 
 
27 (7) 27 (6) 
 
27 (6) 26 (6) 
Smoker % 35% 30% 
 
19% 17% 
 
19% 16% 
Duration (years)  0.8 (1.3) 0.8 (1.4) 
 
13 (10) 13 (10) 
 
10 (11) 11 (11) 
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Disability (HAQ)  1.1 (0.8) 1.0 (0.7) 
 
2.0 (0.6) 2.0 (0.6) 
 
1.4 (0.8) 1.3 (0.8) 
DAS28  4.6 (1.6) 4.7 (1.5) 
 
6.6 (1.0) 6.6 (1.0) 
 
5.0 (1.3) 4.8 (1.3) 
CRP  23 (32) 24 (31) 
 
47 (44) 48 (44) 
 
29 (31) 29 (34) 
Seropositive % 63% 61%   65% 65%   58% 60% 
 
Table 1: Sample sizes, means (standard deviations) and percentages are shown for baseline demographics. Complete cases; the subgroup of Data Set for 
whom SF36-Bodily Pain data are available for all time points. BMI= body mass index; DAS28= Disease Activity Score in 28 joints; HAQ=health assessment 
questionnaire for disability; CRP= C-reactive protein.  
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Table 2: Summary of the model selection process  
 
  Number of latent trajectories in GMM 
  1 trajectory 2 trajectories 
3 
trajectories 
4 
trajectories 
ERAN 
    
AIC 7723 7687 7682 7685 
BIC 7748 7723 7729 7742 
ssBIC 7726 7691 7688 7692 
Entropy 
 
0.709 0.665 0.63 
LMR-LRT 
 
<0.001 0.030 0.636 
BLRT 
 
<0.001 0.013 0.654 
Largest trajectory (%) 264 (100%) 147 (56%) 155 (59%) 106 (40%) 
Second largest trajectory 
(%)  
117 (44%) 60 (23%) 71 (27%) 
Third largest trajectory (%) 
  
49 (19%) 52 (20%) 
Fourth largest trajectory 
(%)    
35 (13%) 
     BSRBR-Biologics 
    AIC 152407 152299 152237 Not done 
BIC 152480 152390 152346 
ssBIC 152442 152342 152289 
Entropy 
 
0.595 0.714 
LMR-LRT 
 
0.0491 0.0002 
BLRT 
 
<0.0001 <0.0001 
Largest trajectory (%) 3138 (100%) 2483 (79%) 2430 (77%) 
Second largest trajectory 
 
655 (21%) 654 (21%) 
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(%) 
Third largest trajectory (%) 
  
54 (2%) 
     BSRBR-Non-Biologics 
    AIC 28623 28586 28563 Not done 
BIC 28676 28652 28642 
ssBIC 28638 28605 28585 
Entropy 
 
0.677 0.758 
LMR-LRT 
 
<0.0001 0.004 
BLRT 
 
<0.0001 <0.0001 
Largest trajectory (%) 605 (100%) 441(73%) 445 (74%) 
Second largest trajectory 
(%) 
 
164 (27%) 139 (23%) 
Third largest trajectory (%) 
  
21 (3%) 
 
Table 2: Indices and statistics for GMMs using complete cases are shown for models with 
different numbers of trajectories.  ERAN=Early RA Network; BSRBR=British Society for 
Rheumatology Biologics Register; AIC= Akaike’s information criterion; BIC= Bayesian 
information criterion; ssBIC= sample size-adjusted BIC; LRT= Lo-Mendell-Rubin likelihood 
ratio test p value; BLRT= Bootstrapped likelihood ratio test P value. The selected model for 
each cohort study is shown in bold. 
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Table 3: Comparison of baseline variables between trajectories 
 
  ERAN   BSRBR-Biologics   BSRBR-Non-Biologics 
  Low 
pain 
Persistent 
pain 
Resolving 
pain 
Heterogeneity 
p value   
Resolving 
pain 
Persistent 
pain 
Heterogeneity 
p value   
Resolving 
pain 
Persistent 
pain 
Heterogeneity 
p value 
Age 55 (15) 57 (13) 55 (16) 0.451 
 
54 (12) 58 (11) <0.001 
 
59 (12) 62 (11) <0.001 
Female 70% 74% 63% 0.329 
 
76% 77% 0.659 
 
73% 75% 0.382 
BMI 
25.8 
(3.7) 
28.7 (5.7) 26.6 (4.5) <0.001 
 
25.7 (5.6) 27.1 (6.8) <0.001 
 
25.9 (4.9) 27.3 (5.8) <0.001 
Current smoker 30% 33% 29% 0.819 
 
15% 20% <0.001 
 
16% 20% <0.001 
Duration 10 (17) 9 (11) 11 (14) 0.554 
 
12 (9) 14 (10) <0.001 
 
7 (9) 11 (11) <0.001 
Seropositive 55% 62% 68% 0.459 
 
63% 65% 0.134 
 
57% 58% 0.678 
DAS28 3.4 (1.2) 5.0 (1.4) 5.0 (1.4) <0.001 
 
6.4 (1.0) 6.6 (1.0) <0.001 
 
4.5 (1.3) 5.1 (1.3) <0.001 
VAS-GH 21 (16) 51 (23) 46 (25) <0.001 
 
70 (20) 73 (19) 0.442 
 
42 (25) 55 (23) <0.001 
TJC 3 (4) 9 (7) 7 (7) <0.001 
 
14 (7) 16 (7) <0.001 
 
6 (6) 8 (7) <0.001 
SJC 4 (5) 7 (6) 7 (6) 0.002 
 
11 (6) 11 (6) 0.214 
 
5 (5) 6 (5) 0.431 
ESR 26 (22) 33 (26) 43 (32) 0.017 
 
45 (28) 47 (29) 0.030 
 
31 (24) 34 (23) 0.094 
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CRP 11 (23) 27 (30) 31 (39) 0.022 
 
46 (41) 48 (45) 0.414 
 
26 (32) 29 (31) 0.259 
DAS28-P 
0.33 
(0.12) 
0.45 
(0.10) 
0.41 
(0.09) 
<0.001 
 
0.47 
(0.08) 
0.48 
(0.07) 0.001  
0.40 
(0.11) 
0.44 
(0.10) <0.001 
Tender-Swollen 
Difference 
-0.60 
(4.40) 
2.74 
(6.41) 
0.11 
(5.77) 
<0.001 
 
3.22 
(7.06) 
4.45 
(7.18) <0.001  
0.75 
(5.02) 
2.70 
(5.79) <0.001 
Comorbidities 48% 70% 57% 0.029 
 
48% 64% <0.001 
 
50% 67% <0.001 
Disability (HAQ) 
0.38 
(0.41) 
1.31 
(0.72)* 
1.03 
(0.62)* 
<0.001 
 
1.7 (0.6) 2.1 (0.5) <0.001 
 
0.8 (0.6) 1.6 (0.7) <0.001 
SF36 (normed) 
    
        Bodily Pain 48 (6) 30 (9) 30 (8) <0.001 40 (9) 30 (7) <0.001 28 (8) 24 (7) <0.001 
Physical function  44 (9) 25 (14) 30 (12) <0.001 
 
20 (12) 14 (10) <0.001 
 
37 (12) 22 (12) <0.001 
Vitality  54 (8) 39 (10) 43 (10) <0.001 
 
35 (10) 32 (10) <0.001 
 
46 (10) 38 (10) <0.001 
Mental health  55 (8) 45 (11) 49 (9) <0.001 
 
44 (11) 40 (11) <0.001 
 
52 (9) 45 (11) <0.001 
 
 
Table 3: Mean (standard deviation) or percentages are shown for each latent trajectory at baseline. P values for heterogeneity between trajectories are 
shown. In the ERAN data set, significance in pairwise comparisons between Persistent Pain and Resolving Pain trajectories are indicated (* p<0.05 with 
Bonferonni correction). Higher scores in the SF36 subscales reflect better quality of life. BMI= body mass index; DAS28= Disease Activity Score in 28 joints; 
VAS-GH=visual analogue scale; TJC= tender joint count; SJC= swollen joint count; HAQ=health assessment questionnaire for disability; ESR= erythrocyte 
sedimentation rate; CRP= C-reactive protein; Seropositive= positive for Rheumatoid factor or citrullinated proteins. 
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Table 4: Multinomial logistic regression for Persistent Pain trajectory in each cohort 
 
  
ERAN Persistent Pain (vs Low 
Pain) 
ERAN Persistent Pain (vs 
Resolving Pain) 
 
BSRBR-Biologics 
 
BSRBR-Non-Biologics 
  aOR (95% CI) p aOR (95% CI) p 
 
aOR (95% CI) p 
 
aOR (95% CI) p 
Age 1.01 (0.99 - 1.04) 0.340 0.99 (0.98 - 1.01) 0.550 
 
1.02 (1.01 - 1.03) <0.001 
 
1.01 (0.99 - 1.02) 0.314 
BMI 1.02 (0.95 - 1.10) 0.553 1.00 (0.96 - 1.05) 0.947 
 
1.03 (1.02 - 1.05) <0.001 
 
1.03 (1.00 - 1.06) 0.029 
Duration 1.02 (0.97 - 1.06) 0.457 0.99 (0.98 - 1.00) 0.123 
 
1.02 (1.01 - 1.02) <0.001 
 
1.03 (1.01 - 1.05) <0.001 
Current smoker 1.16 (0.52 - 2.56) 0.717 1.83 (1.05 - 3.18) 0.032 
 
1.72 (1.41 - 2.11) <0.001 
 
1.34 (0.89 - 2.02) 0.156 
Ex-smoker 4.65 (1.73 - 12.50) 0.002 1.52 (0.86 - 2.67) 0.146 
 
1.17 (1.00 - 1.37) 0.045 
 
1.64 (1.18 - 2.28) 0.003 
DAS28 0.91 (0.67 - 1.24) 0.542 0.54 (0.69 - 1.02) 0.073 
 
0.91 (0.84 - 0.99) 0.019 
 
0.97 (0.86 - 1.10) 0.629 
Disability 
(HAQ) 5.43 (2.44 - 12.05) <0.001 2.31 (1.51 - 3.56) <0.001 
 
2.36 (2.05 - 2.73) <0.001 
 
2.52 (1.91 - 3.32) <0.001 
CoMorbidity 1.18 (0.57 - 2.48) 0.655 1.28 (0.78 - 2.09) 0.332 
 
1.39 (1.20 - 1.60) <0.001 
 
1.21 (0.89 - 1.65) 0.215 
Bodily Pain 0.76 (0.70 - 0.81) <0.001 1.02 (0.99 - 1.06) 0.224 
 
0.98 (0.97 - 0.99) <0.001 
 
0.93 (0.91 - 0.95) <0.001 
Vitality 0.99 (0.95 - 1.03) 0.579 0.97 (0.94 - 1.00) 0.028 
 
1.00 (0.99 - 1.01) 0.704 
 
0.99 (0.98 - 1.01) 0.561 
Mental Health 1.02 (0.98 - 1.07) 0.318 0.99 (0.96 - 1.02) 0.425 
 
0.98 (0.97 - 0.99) <0.001 
 
0.97 (0.95 - 0.99) 0.001 
 
Table 4: In ERAN the adjusted odds ratios (aOR) for Persistent Pain are displayed, compared to both of the other trajectories. Persistent Pain was used as the reference 
category, and the aOR and CI’s were then inverted. Multinomial logistic regression was performed; and each aOR indicates the change in risk per unit increase (per year of 
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age, unit of BMI, year of duration, unit of DAS28, unit of HAQ, per point of SF36 subscale). Higher scores in the SF36 subscales reflect better quality of life. Categorical 
variables aOR’s showed risk directly compared to a reference category (No comorbidities and Never smoked). Statistically significant findings are presented in bold. 
 
 
